Aspire Biopharma Holdings Business Summary

Aspire Biopharma Holdings, Inc. (ASBP) is an early-stage biopharmaceutical company that generates revenue through a dual-track model comprising a Consumer Division and a Pharmaceutical Development segment. The company’s primary revenue stream currently stems from the commercialization of its "BUZZ BOMB" caffeine delivery units, while its long-term value proposition is built on licensing and commercializing proprietary, patent-pending sublingual delivery technologies. These technologies utilize nanotechnology and micelle-based mechanisms to enable rapid absorption of active pharmaceutical ingredients (APIs) directly into the bloodstream, bypassing the gastrointestinal tract. Aspire’s primary business segments focus on emergency-use therapeutics, such as sublingual aspirin for acute myocardial infarction, and symptom management formulations like ondansetron for nausea. Within the competitive landscape, Aspire contends with micro-cap biotech innovators such as Quince Therapeutics, CalciMedica, Hoth Therapeutics, and Tempest Therapeutics, positioning itself as a specialized player in the rapid-onset, high-dose transmucosal delivery niche. The leadership team is headed by Kraig T. Higginson, who serves as President, CEO, and Chairman of the Board, bringing over four years of prior executive experience with the company and a focus on strategic restructuring. The executive suite includes Chief Financial Officer Ernest J. Scheidemann Jr., a seasoned financial strategist, and Stephen E. Quesenberry, who serves as General Counsel and Corporate Secretary. To bolster its technical pedigree, the company recently added Dr. Mark J. Jaroszeski, a tenured professor at the University of South Florida and a globally recognized expert in drug delivery with 34 U.S. patents, to its scientific team. Aspire is backed by notable institutional support, including a $100 million equity line of credit from Arena Business Solutions Global SPC II, Ltd., and a $21 million private placement completed in February 2026 by a group of select institutional and accredited investors.